EU Launches Faster Process For Approving Variant Vaccines
EMA Outlines Basic Regulatory Requirements
Amid the growing threat posed by variants of the coronavirus, the European Commission has published new rules allowing modified vaccines to be approved more quickly. The UK has identified one version of the B.1.167 virus variant as the most transmissible, although the jury is still out on its ability to evade vaccine protection.
You may also be interested in...
Coronavirus Notebook: EMA Explains How To Get A Modified Vaccine Approved, UK Starts Oxford/AZ Variant Vaccine Trial
Draft legislation on strengthening the European Medicines Agency’s role in health crises has cleared another hurdle, and the European Commission is inviting companies to a matchmaking event aimed at scaling up the development and production of COVID-19 therapeutics.
As the World Health Organization brands the Indian virus a “variant of concern,” the UK is planning to use a lab-grown virus variant in challenge trials of current and new vaccines, and is also investing in new variant vaccine testing facilities. A new study will use Oxford Immunotec’s T cell test to monitor people’s immunological response to infection or vaccination.
The EU institutions are taking steps to preserve the effectiveness of existing vaccines in the face of mutations in the SARS-CoV-2 virus.